CrystalGenomics, Inc. - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

CrystalGenomics, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'CrystalGenomics, Inc. - Product Pipeline Review - 2014', provides an overview of the CrystalGenomics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CrystalGenomics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CrystalGenomics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CrystalGenomics, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the CrystalGenomics, Inc.'s pipeline products

Reasons to buy

- Evaluate CrystalGenomics, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CrystalGenomics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CrystalGenomics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CrystalGenomics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CrystalGenomics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CrystalGenomics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
CrystalGenomics, Inc. Snapshot 5
CrystalGenomics, Inc. Overview 5
Key Information 5
Key Facts 5
CrystalGenomics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
CrystalGenomics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
CrystalGenomics, Inc. - Pipeline Products Glance 11
CrystalGenomics, Inc. - Late Stage Pipeline Products 11
Phase III Products/Combination Treatment Modalities 11
CrystalGenomics, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
CrystalGenomics, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
CrystalGenomics, Inc. - Drug Profiles 15
polmacoxib 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CG-200745 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CG-400549 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CG-026806 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CG-301269 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Drug Targeting Kynurenine 3-Monooxygenase 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Small Molecule To Inhibit Bruton Agammaglobulinemia Tyrosine Kinase For Cancer And Rheumatoid Arthritis 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Small Molecule To Inhibit Hypoxia Inducible Factor Prolyl-4-Hydroxylase For Hematological Disorders 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Small Molecule Targeting Metalloproteinases 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Small Molecule Targeting Nuclear Hormone Receptors 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Small Molecule Targeting Phosphodiesterases 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Small Molecule To Inhibit Spleen Tyrosine Kinase For Rheumatoid Arthritis 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecules To Inhibit MBL For Bacterial Infections 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecules to Inhibit TNIK for Cancer 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Inhibit UBA5 for Cancer 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CrystalGenomics, Inc. - Pipeline Analysis 32
CrystalGenomics, Inc. - Pipeline Products by Target 32
CrystalGenomics, Inc. - Pipeline Products by Route of Administration 34
CrystalGenomics, Inc. - Pipeline Products by Molecule Type 35
CrystalGenomics, Inc. - Pipeline Products by Mechanism of Action 36
CrystalGenomics, Inc. - Recent Pipeline Updates 38
CrystalGenomics, Inc. - Dormant Projects 41
CrystalGenomics, Inc. - Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
CrystalGenomics, Inc., Key Information 5
CrystalGenomics, Inc., Key Facts 5
CrystalGenomics, Inc. - Pipeline by Indication, 2014 7
CrystalGenomics, Inc. - Pipeline by Stage of Development, 2014 9
CrystalGenomics, Inc. - Monotherapy Products in Pipeline, 2014 10
CrystalGenomics, Inc. - Phase III, 2014 11
CrystalGenomics, Inc. - Phase II, 2014 12
CrystalGenomics, Inc. - Preclinical, 2014 13
CrystalGenomics, Inc. - Discovery, 2014 14
CrystalGenomics, Inc. - Pipeline by Target, 2014 32
CrystalGenomics, Inc. - Pipeline by Route of Administration, 2014 34
CrystalGenomics, Inc. - Pipeline by Molecule Type, 2014 35
CrystalGenomics, Inc. - Pipeline Products by Mechanism of Action, 2014 37
CrystalGenomics, Inc. - Recent Pipeline Updates, 2014 38
CrystalGenomics, Inc. - Dormant Developmental Projects,2014 41